25C-NBOMe - Revision history

Rossdonaldson1 at 19:52, 24 April 2024

2024-04-24T19:52:20Z

← Older revision		Revision as of 19:52, 24 April 2024
Line 1:		Line 1:
	''Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound''		''Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound''

	==Background==		==Background==
	[[File:25C-NBOMe.png\|thumb\|25C-NBOMe]]		[[File:25C-NBOMe.png\|thumb\|25C-NBOMe]]

Rossdonaldson1: /* Differential Diagnosis */

2021-01-12T20:27:32Z

Differential Diagnosis

← Older revision		Revision as of 20:27, 12 January 2021
Line 38:		Line 38:
	==Differential Diagnosis==		==Differential Diagnosis==
	{{Drugs of abuse types}}		{{Drugs of abuse types}}
			{{Hallucinogen types}}

	==Evaluation==		==Evaluation==

Rossdonaldson1: /* Clinical Features */

2021-01-12T20:26:47Z

Clinical Features

← Older revision		Revision as of 20:26, 12 January 2021
Line 19:		Line 19:
	*Sense of numbness of tongue and mouth		*Sense of numbness of tongue and mouth
	*Euphoria		*Euphoria
	*Visual/Auditory hallucinations		*Visual/Auditory [[hallucinations]]
	*Stimulation +/- tremors, bruxism		*Stimulation +/- tremors, bruxism
	*[[Serotonin Syndrome]] ([[altered mental status]], [[Hyperthermia]], rigidity, autonomic instability)<ref>Boyer EW, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112-20</ref>		*[[Serotonin Syndrome]] ([[altered mental status]], [[Hyperthermia]], rigidity, autonomic instability)<ref>Boyer EW, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112-20</ref>
Line 35:		Line 35:
	*[[Acute Renal Failure]]		*[[Acute Renal Failure]]
	*[[Metabolic Acidosis]]		*[[Metabolic Acidosis]]


	==Differential Diagnosis==		==Differential Diagnosis==

Rossdonaldson1: /* Background */

2019-09-06T02:51:54Z

Background

← Older revision		Revision as of 02:51, 6 September 2019
Line 2:		Line 2:

	==Background==		==Background==
			[[File:25C-NBOMe.png\|thumb\|25C-NBOMe]]
			[[File:25C-NBOMe blotter.jpg\|thumb\|Blotter paper containing 25C-NBOMe]]
	*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine		*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
	*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime		*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime
Line 12:		Line 14:
	*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>		*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>
	*The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>		*The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>

	~~[[File:25C-NBOMe.png\|thumb\|25C-NBOMe]]~~

	==Clinical Features==		==Clinical Features==

Rossdonaldson1: /* Clinical Features */

2019-09-06T02:49:51Z

Clinical Features

← Older revision		Revision as of 02:49, 6 September 2019
Line 35:		Line 35:
	*[[Acute Renal Failure]]		*[[Acute Renal Failure]]
	*[[Metabolic Acidosis]]		*[[Metabolic Acidosis]]


			==Differential Diagnosis==
			{{Drugs of abuse types}}

	==Evaluation==		==Evaluation==

Mholtz at 03:42, 9 July 2017

2017-07-09T03:42:27Z

← Older revision		Revision as of 03:42, 9 July 2017
Line 1:		Line 1:
	~~[[File:25C-NBOMe.png\|thumbnail\|25C-NBOMe]]~~		''Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound''
	Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound all of which are Schedule I controlled substances in the United States. They were first synthesized in Germany by Ralf Heim in 2004<ref>Heim R. “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur”. :Entwicklung eines neuen Struktur-Wirkungskonzepts. Berlin, Freie University, Dissertation, 2003</ref>
	==Background==		==Background==
	*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine		*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
	*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime		*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime
	*Potent partial agonist of 5-HT2A receptor<ref name="pharm">Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:734749.</ref>		*Potent partial agonist of 5-HT2A receptor<ref name="pharm">Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:734749.</ref>
	*Member of new class of toxic phenethylamine derivatives (NBOMe) with similar effects to [[LSD]] ~~which is commonly ingested~~ ingested orally or sublingually; can also be ~~ingested~~ nasally, parenterally, vaginally, rectally.		*First synthesized in Germany by Ralf Heim in 2004<ref>Heim R. “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur”. :Entwicklung eines neuen Struktur-Wirkungskonzepts. Berlin, Freie University, Dissertation, 2003</ref>
			*Member of new class of toxic phenethylamine derivatives (NBOMe) with similar effects to [[LSD]]
			*Commonly ingested orally or sublingually; can also be taken nasally, parenterally, vaginally, rectally.
	*Dose of 50-200 micrograms causes hallucinogenic effects<ref name="pharm"></ref>		*Dose of 50-200 micrograms causes hallucinogenic effects<ref name="pharm"></ref>
	*Onset 0-15 mins, peak 30-90 mins, total duration 4-10 hours<ref name="pharm"></ref>		*Onset 0-15 mins, peak 30-90 mins, total duration 4-10 hours<ref name="pharm"></ref>

	*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>		*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>
			*The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>

	*The 25I- ~~version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al~~. ~~Postmortem detection of 25I~~-NBOMe ~~[2-(4-iodo-2,5-dimethoxyphenyl)methyl~~] ~~ethanamine~~] ~~in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>~~		[[File:25C-NBOMe.png\|thumb\|25C-NBOMe]]

	==Clinical Features==		==Clinical Features==
Line 34:		Line 36:
	*[[Metabolic Acidosis]]		*[[Metabolic Acidosis]]

	==~~Workup~~==		==Evaluation==
	{{Hallucinogen workup}}		{{Hallucinogen workup}}

Line 45:		Line 47:
	*'''[[Seizure]]'''		*'''[[Seizure]]'''
	**[[Benzodiazepines]]		**[[Benzodiazepines]]
	**manage airway as indicated
	*[[Hyperthermia]]:		*[[Hyperthermia]]:
	**~~ice packs, cold IVF~~		**Passive cooling measures

	==Disposition==		==Disposition==
	*Admit for monitoring on all patients with continuing agitation requiring escalating doses of sedation		*Admit for monitoring on all patients with continuing agitation requiring escalating doses of sedation
	*~~Admit for fluids in patient with monitoring~~		*Consider discharge if complete resolution of symptoms
	*Patient with full resolution of symptoms ~~can be discharged from the emergency department~~

	==See Also==		==See Also==
	*[[LSD]]		*[[Lysergic acid diethylamide (LSD)]]
	*[[Ecstasy (MDMA)]]		*[[Ecstasy (MDMA) toxicity]]
	*[[Hallucinations]]		*[[Hallucinations]]
	*[[Hallucinogens]]		*[[Hallucinogens]]

Rossdonaldson1: Text replacement - "AMS" to "altered mental status"

2016-07-31T05:54:55Z

Text replacement - "AMS" to "altered mental status"

← Older revision		Revision as of 05:54, 31 July 2016
Line 19:		Line 19:
	*Visual/Auditory hallucinations		*Visual/Auditory hallucinations
	*Stimulation +/- tremors, bruxism		*Stimulation +/- tremors, bruxism
	*[[Serotonin Syndrome]] ([[~~AMS~~]], [[Hyperthermia]], rigidity, autonomic instability)<ref>Boyer EW, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112-20</ref>		*[[Serotonin Syndrome]] ([[altered mental status]], [[Hyperthermia]], rigidity, autonomic instability)<ref>Boyer EW, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112-20</ref>
	*Confusion		*Confusion
	*Agitation		*Agitation

Neil.m.young: Text replacement - "==Treatment==" to "==Management=="

2016-07-07T16:21:17Z

Text replacement - "==Treatment==" to "==Management=="

← Older revision		Revision as of 16:21, 7 July 2016
Line 37:		Line 37:
	{{Hallucinogen workup}}		{{Hallucinogen workup}}

	==~~Treatment~~==		==Management==
	*ABCs		*ABCs
	*IV, O2, monitor		*IV, O2, monitor

Neil.m.young: Text replacement - "==Sources==" to "==References=="

2016-06-26T21:22:46Z

Text replacement - "==Sources==" to "==References=="

← Older revision		Revision as of 21:22, 26 June 2016
Line 60:		Line 60:
	*[[Hallucinogens]]		*[[Hallucinogens]]

	==~~Sources~~==		==References==
	<references/>		<references/>

	[[Category:Toxicology]]		[[Category:Toxicology]]

Ostermayer: Text replacement - "Category:Tox" to "Category:Toxicology"

2016-03-22T16:23:35Z

Text replacement - "Category:Tox" to "Category:Toxicology"

← Older revision		Revision as of 16:23, 22 March 2016
Line 63:		Line 63:
	<references/>		<references/>

	[[Category:~~Tox~~]]		[[Category:Toxicology]]